Canada markets open in 9 hours 13 minutes

Aequus Pharmaceuticals Inc. (AQS.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.05000.0000 (0.00%)
At close: 11:03AM EDT
Full screen
Previous Close0.0500
Bid0.0450 x 0
Ask0.0500 x 0
Day's Range0.0500 - 0.0500
52 Week Range0.0200 - 0.1300
Avg. Volume52,465
Market Cap6.632M
Beta (5Y Monthly)0.63
PE Ratio (TTM)N/A
EPS (TTM)-0.0130
Earnings DateNov 01, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
  • GlobeNewswire

    Aequus Reports Second Quarter 2022 Financial Highlights and General Update

    VANCOUVER, British Columbia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, has hired Rabin Ramanjooloo as Director of Operations and today reported financial results for the quarter ended June 30, 2022 (“Second Quarter 2022”) and associated Company developments. Unless otherwise noted, all figures are in Canadian

  • GlobeNewswire

    Press Release for Early Warning Report Regarding Aequus Pharmaceuticals Inc.

    VANCOUVER, British Columbia, July 23, 2022 (GLOBE NEWSWIRE) -- Doug Janzen, of 2820 – 200 Granville St., Vancouver, BC, V6C 1S4, today announced that on Tuesday, July 19, 2022, he acquired ownership (the “Acquisition”) of 100,000 common shares (“Common Shares”) in the capital of Aequus Pharmaceuticals Inc. (Address: 2820 – 200 Granville St., Vancouver, BC V6C 1S4) (“Aequus”) through the facilities of the TSX Venture Exchange. Mr. Janzen acquired 99,000 Common Shares at a price of $0.07 per Commo

  • CNW Group

    IIROC Trading Resumption - AQS

    Trading resumes in: